|
| FDA Grants Priority Review of Gamunex(R) as a Treatment for Neurological Disorder CIDP |
8 May 08, 18:17 |
|
| Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted a Priority Review of Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). |
| more |
|
